Shire announced a long-term, broad based, multi-indication research collaboration in rare diseases with Fondazione Telethon for research carried out at the Telethon Institute of Genetics and Medicine, or TIGEM. This alliance will facilitate research on 13 undisclosed rare disease indications and has the potential to add multiple, novel therapeutic candidates into Shire's early stage pipeline. Under the terms of the agreement, Shire will provide $22M funding over five years for several research projects that collectively address a number of different lysosomal storage disorders and neurodegenerative diseases. Successful projects that arise from this research will be incorporated into Shire's development pipeline and benefit from additional Shire investment and resources.
- Science, Social Science, & Humanities